Pricing, Reimbursement & Market Access Publications - Pharmaceutical and Biotech industries

Supported by our experienced medical writers and editors, we work with clients to ensure that the evidence generated is published. We develop a range of peer-reviewed publications, conference abstracts, posters, and manuscripts.

The difference between regulatory and market access decisions on treatment availability for new drugs in six common cancers across Australia, Canada, and Europe

Jan McKendrick, Ioannis Katsoulis, Xirong Song, Jeanni van Loon, et al.

Do countries with similar GDPs and health expenditures reimburse the same cancer drugs?

Jan McKendrick, Ioannis Katsoulis, Xirong Song, Jeanni van Loon, et al.

Assessing the implications of the NICE budget impact test: how many oncology regimens will be affected and what will be the impact on patient outcomes?

Harriet Tuson, Anja Dunsch, and Xirong Song

The role of companion diagnostics in HTAs of drugs in France, Germany, and the UK

Clare Jones, Orestis Lazos, and Merel Gijsen

Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada

Jan McKendrick, Ioannis Katsoulis, Xirong Song, Jeanni van Loon, et al.

Abstract 1124P_PR, ESMO 2017

Poster

Investigating discrepancies in assessments of PFS between study investigators and independent reviewers

Clare Jones, Giles Monnickendam, Juan Barrientos

Abstract 1130P, ESMO 2017

Poster

Indirect treatment comparison of talimogene laherparepvec compared with ipilimumab and vemurafenib for the treatment of patients with metastatic melanoma

Casey Quinn, Amber Kudlac, et al.

Advances in Therapy 2016
DOI: 10.1007/s12325-016-0313-x

Journal article

Relative efficacy of granulocyte-macrophage colony-stimulating factor, dacarbazine, and glycoprotein 100 in metastatic melanoma: an indirect treatment comparison

Casey Quinn, Amber Kudlac, et al.

Advances in Therapy 2016
DOI: 10.1007/s12325-016-0464-9

Journal article

Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.

Jan McKendrick, Merel Gijsen, et al.

Journal of Medical Economics 2016
DOI: 10.3111/13696998.2016.1148043

Journal article

Years of life lost due to metastatic melanoma in 12 countries

Aminata Thiama, Casey Quinn, et al.

Journal of Medical Economics 2015
DOI: 10.3111/13696998.2015.1115764

Journal article

Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey

Jan McKendrick, Heather Wieffer, et al.

Atherosclerosis 2015
245:111 DOI: 10.1186/s12955-015-0377-3

Journal article

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom

Mike Aristides, Casey Quinn, et al.

Health and Quality of Life Outcomes 2015
13:181 DOI: 10.1186/s12955-015-0377-3

Journal article

Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Deborah Saltman, et al.

BMC Cancer 2015
15:771 DOI: 10.1186/s12885-015-1745-4

Journal article

Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists

Clare Jones, Genevieve Clapton, Deborah Saltman, et al.

European Journal of Cancer Care 2015
24:867 DOI: 10.1111/ecc.12359

Journal article

info@prmaconsulting.com
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798
Terms and conditions
Company registration number: 05893400

Follow us


Members of

Terms & conditions
Privacy policy
Cookie policy